EUVIMEDEUVIMED entdecken
Open Access

Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML

Eunice S Wang iD, Aaron D Goldberg iD, Martin Tallman, Roland B Walter iD, Chatchada Karanes, Karamjeet Sandhu, Carlos E Vigil iD, Robert Collins iD, Vinay Jain, Richard M Stone iD

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Eunice S Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Antineoplastic Combined Chemotherapy Protocols, Leukemia, Myeloid, Acute, Mutation. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Crenolanib is a second-generation tyrosine kinase inhibitor with activity against FLT3-ITD– and TKD-mutant AML. We conducted a trial of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML. METHODS Eligible patients were 18 years and older. Induction chemotherapy consisted of cytarabine (100 mg/m 2 ) continuous infusion on days 1-7 and anthracycline (daunorubicin 60-90 mg/m 2 or idarubicin 12 mg/m 2 , once daily) on days 1-3 followed by consolidation with high-dose cytarabine (1-3 g/m 2 twice daily on days 1, 3, 5) and/or allogeneic transplant. Crenolanib (100 mg thrice a day) was given from day 9 until 72 hours before the next cycle, after consolidation, and for 12 months after consolidation or transplant. RESULTS Forty-four patients (median age, 57; range, 19-75 years) were enrolled. Thirty-six had FLT3-ITD, and 11 had FLT3-TKD mutations. European LeukemiaNet 2017 disease risk was favorable in 34%, intermediate in 30%, and adverse in 36%. The overall response rate was 86% (complete remission [CR], 77%; CR with incomplete count recovery [CRi], 9%): 90% in patients 60 years and younger and 80% in older patients. Measurable residual disease–negative CR/CRi rates were 89% and 45%, respectively. With a 45-month follow-up, median overall survival has not been reached and the median event-free survival was 44.7 months. Among younger patients, the estimated 3-year survival was 71.4% with 15% cumulative incidence of relapse. Treatment-related serious adverse events included febrile neutropenia, diarrhea, and nausea. The median time to platelets ≥100,000/µL and absolute neutrophil count ≥1,000/µL during induction was 29 and 32 days, respectively. No new FLT3-mutant clones were detected at relapse in patients completing consolidation. CONCLUSION Crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML results in high rate of deep responses and long-term survival with acceptable toxicity. A randomized trial of crenolanib versus midostaurin plus chemotherapy in younger patients is ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteMutationHumansMiddle AgedAdultFemaleMaleAgedYoung AdultPiperidinesBenzimidazolesInduction ChemotherapyCytarabine

Substanzen

fms-Like Tyrosine Kinase 3PiperidinesBenzimidazolesCytarabine

Autor:innen und Institutionen

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • City of Hope National Medical Center, Duarte, CA.
  • University of Iowa, Iowa City, IA.
  • University of Texas Southwestern, Dallas, TX.

ORCID-Profile: Eunice S Wang, Aaron D Goldberg, Roland B Walter, Carlos E Vigil, Robert Collins, Richard M Stone

Förderung

  • NCI NIH HHS

Zitieren

APA

Wang, E. S., Goldberg, A. D., Tallman, M., Walter, R. B., Karanes, C., Sandhu, K., Vigil, C. E., Collins, R., Jain, V., & Stone, R. M. (2024). Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01061

Vancouver

Wang ES, Goldberg AD, Tallman M, Walter RB, Karanes C, Sandhu K, et al. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01061

BibTeX
@article{Wang2024,
  author = {Wang, Eunice S and Goldberg, Aaron D and Tallman, Martin and Walter, Roland B and Karanes, Chatchada and Sandhu, Karamjeet and Vigil, Carlos E and Collins, Robert and Jain, Vinay and Stone, Richard M},
  title = {Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01061}
}
Kostenlos starten →